Dr Andrew Hogan

Biology, Human Health Institute

Senior Lecturer
Associate Professor

Biosciences & Electronic Engineering Building
(01) 708 6118


Dr Andrew Hogan joined Maynooth University as a Assistant Professor in 2017. And is Principle Investigator with the Metabolic Immunology Research Group.

He completed his undergraduate and post-graduate studies in Maynooth University, before being awarded a Newman Fellowship in Obesity with Prof Donal O'Shea in UCD and St Vincent's Hospital.

In 2012, he was awarded a Research Fellowship from the National Children's Research Centre and established the Childhood Obesity Immunology Group. He has also been a research fellow in the lab of Prof Lydia Lynch in Harvard Medical School. 

The Metabolic Immunology Research group focuses on the impact of Obesity on the immune system and the development of co-morbid diseases such as Type II Diabetes and Cancer.

Currently the group is comprised of 3 Post Doctoral Scientists, 3 PhD Students and 2 Research Assistants.

The group has strong clinical partnerships with Prof Donal O'Shea (St Vincent's University Hospital), Prof Declan Cody (Our Lady's Children's Hospital Crumlin) and Dr Anne Marie Tobin (Tallaght Hospital).

The group is funded by grants from the National Children's Research Centre, Health Research Board, Dublin Skin Hospital & Enterprise Ireland.

Research Interests

Ireland has one of the highest rates of childhood obesity in the world. One in four Irish school-going children are either overweight or obese. These children are at a higher risk of developing cardiovascular, metabolic and cancer related co-morbidities. Furthermore, children who are obese are highly likely to be obese in adulthood. The purpose of our research is to understand how and aim to develop successful interventions to prevent the establishment of overt chronic disease.

The Obesity Immunology research programme aims to do this by investigating (1) how obesity impacts the immune system, driving inflammation and dysregulation, which underpins the development of the aforementioned diseases. (2) Our research also 
focuses on how the immune system regulates metabolism (from insulin signalling to adiposity), better understanding of these processes will allow us to identify new therapeutic strategies for obesity and its associated diseases.

Research Projects

Title Role Description Start date End date Amount
Novel Approach to the Development of Food Products for Pre-Diabetics and Those With Impaired Glucose Tolerance Co-PI 01/08/2018 31/07/2020 285000
Immune dysregulation in Type 1 diabetes. Principle Investigator 09/07/2018 12/07/2020
Inflammatory markers of antipsychotic weight gain and cardiometabolic dysfunction in youth mental health disorders Principle Investigator 01/02/2018 30/01/2021
Effect of Glucagon like peptide-1 therapy on obesity driven inflammation and co- morbid inflammatory conditions. Scientific Lead Obesity is a global epidemic and increases the risk of developing diseases such as type 2 diabetes mellitus (T2DM), heart disease and cancer. In lean healthy individuals the host immune system is equipped with mechanisms to deal with insults such as inflammation or malignant cells. Obese people are at greater risk of disease as their immune system is altered. Chronic inflammation plays a major role in obesity and is now seen in obese children. This results in inflamed tissues, exhausted immune cells and ultimately inflammatory disease. Glucagon like peptide-1 (GLP-1) is a gut hormone now used in the treatment of T2DM. We have reported that GLP-1 impacts inflammation and the immune system. In this study we will look in detail at how GLP-1 impacts inflammation in patients with T2DM and other inflammatory conditions including psoriasis, arthritis and asthma. We will also look in vitro at the effect of GLP-1 on cells from obese children. This will determine if GLP-1 therapy plays a role in treating the inflammation present in obesity and its co-morbid inflammatory diseases. This in turn could have major implications for practice, offering a new treatment pathway for those with T2DM and co-morbid inflammatory diseases. 01/05/2015 30/04/2018

Peer Reviewed Journal

Year Publication
2011 Hogan A.; O'Reilly V.; Dunne M.; Dere R.; Zeng S.; O'Brien C.; Amu S.; Fallon P.; Exley M.; O'Farrelly C.; Zhu X.; Doherty D. (2011) 'Activation of human invariant natural killer T cells with a thioglycoside analogue of α-galactosylceramide'. Journal of Clinical Immunology, 140 (2):196-207. [DOI] [Full-Text]
2018 Brennan K; O'Leary BD; Mc Laughlin D; Breen EP; Connolly E; Ali N; O'Driscoll DN; Ozaki E; Mahony R; Mulfaul K; Ryan AM; Ni Chianain A; McHugh A; Molloy EJ; Hogan AE; Paran S; McAuliffe FM; Doyle SL; (2018) 'Type 1 IFN Induction by Cytosolic Nucleic Acid Is Intact in Neonatal Mononuclear Cells, Contrasting Starkly with Neonatal Hyporesponsiveness to TLR Ligation Due to Independence from Endosome-Mediated IRF3 Activation'. Journal of Immunology, . [DOI] [Full-Text]
2017 Boulenouar, S; Michelet, X; Duquette, D; Alvarez, D; Hogan, AE; Dold, C; O'Connor, D; Stutte, S; Tavakkoli, A; Winters, D; Exley, MA; O'Shea, D; Brenner, MB; von Andrian, U; Lynch, L (2017) 'Adipose Type One Innate Lymphoid Cells Regulate Macrophage Homeostasis through Targeted Cytotoxicity'. Immunity, 46 :273-286. [DOI] [Full-Text]
2017 Tobin, LM; Mavinkurve, M; Carolan, E; Kinlen, D; O'Brien, EC; Little, MA; Finlay, DK; Cody, D; Hogan, AE; O'Shea, D (2017) 'NK cells in childhood obesity are activated, metabolically stressed, and functionally deficient'. Jci Insight, 2 . [DOI] [Full-Text]
2017 Khan F; Mat A; Hogan A; Kent B; Eigenheer S; Corrigan M; O'Shea D; Butler M; (2017) 'Preliminary asthma -related outcomes following glucagon - like peptide 1 agonist therapy'. QJM - Monthly Journal of the Association of Physicians, . [DOI] [Full-Text]
2016 Lynch, L; Hogan, AE; Duquette, D; Lester, C; Banks, A; LeClair, K; Cohen, DE; Ghosh, A; Lu, B; Corrigan, M; Stevanovic, D; Maratos-Flier, E; Drucker, DJ; O'Shea, D; Brenner, M (2016) 'iNKT Cells Induce FGF21 for Thermogenesis and Are Required for Maximal Weight Loss in GLP1 Therapy'. Cell Metabolism, 24 :510-519. [DOI] [Full-Text]
2016 Hams, E; Bermingham, R; Wurlod, FA; Hogan, AE; O'Shea, D; Preston, RJ; Rodewald, HR; McKenzie, ANJ; Fallon, PG (2016) 'The helminth T2 RNase omega 1 promotes metabolic homeostasis in an IL-33-and group 2 innate lymphoid cell-dependent mechanism'. FASEB Journal, 30 :824-835. [DOI] [Full-Text]
2015 Carolan E.; Tobin L.; Mangan B.; Corrigan M.; Gaoatswe G.; Byrne G.; Geoghegan J.; Cody D.; O'Connell J.; Winter D.; Doherty D.; Lynch L.; O'Shea D.; Hogan A. (2015) 'Altered distribution and increased IL-17 production by mucosal-associated invariant T cells in adult and childhood obesity'. Journal of Immunology, 194 (12):5775-5780. [DOI] [Full-Text]
2015 Gaoatswe, G; Kent, BD; Corrigan, MA; Nolan, G; Hogan, AE; McNicholas, WT; O'Shea, D (2015) 'Invariant Natural Killer T Cell Deficiency and Functional Impairment in Sleep Apnea: Links to Cancer Comorbidity'. Sleep, 38 :1629-1634. [DOI] [Full-Text]
2015 Woods C.; Corrigan M.; Gathercole L.; Taylor A.; Hughes B.; Gaoatswe G.; Manolopoulos K.; Hogan A.; O'Connell J.; Stewart P.; Tomlinson J.; O'Shea D.; Sherlock M. (2015) 'Tissue specific regulation of glucocorticoids in severe obesity and the response to significant weight loss following bariatric surgery (BARICORT)'. Journal of Clinical Endocrinology and Metabolism, 100 (4):1434-1444. [DOI] [Full-Text]
2014 Yang, S; Wang, BW; Humphries, F; Hogan, AE; O'Shea, D; Moynagh, PN (2014) 'The E3 Ubiquitin Ligase Pellino3 Protects against Obesity-Induced Inflammation and Insulin Resistance'. Immunity, 41 :973-987. [DOI] [Full-Text]
2014 Carolan, E; Hogan, AE; Corrigan, M; Gaotswe, G; O'Connell, J; Foley, N; O'Neill, LA; Cody, D; O'Shea, D (2014) 'The Impact of Childhood Obesity on Inflammation, Innate Immune Cell Frequency, and Metabolic MicroRNA Expression'. Journal of Clinical Endocrinology and Metabolism, 99 :474-478. [DOI] [Full-Text]
2014 Hogan, AE; Gaoatswe, G; Lynch, L; Corrigan, MA; Woods, C; O'Connell, J; O'Shea, D (2014) 'Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus'. Diabetologia, 57 :781-784. [DOI] [Full-Text]
2013 Mangan B.; Dunne M.; O'Reilly V.; Dunne P.; Exley M.; O'Shea D.; Scotet E.; Hogan A.; Doherty D. (2013) 'Cutting edge: CD1d restriction and Th1/Th2/Th17 cytokine secretion by human Vδ3 T cells'. Journal of Immunology, 191 (1):30-34. [DOI] [Full-Text]
2013 O'Shea D.; Corrigan M.; Dunne M.; Jackson R.; Woods C.; Gaoatswe G.; Moynagh P.; O'Connell J.; Hogan A. (2013) 'Changes in human dendritic cell number and function in severe obesity may contribute to increased susceptibility to viral infection'. International Journal of Obesity, 37 (11):1510-1513. [DOI] [Full-Text]
2013 Zeng, SG; Ghnewa, YG; O'Reilly, VP; Lyons, VG; Atzberger, A; Hogan, AE; Exley, MA; Doherty, DG (2013) 'Human Invariant NKT Cell Subsets Differentially Promote Differentiation, Antibody Production, and T Cell Stimulation by B Cells In Vitro'. Journal of Immunology, 191 :1666-1676. [DOI] [Full-Text]
2012 Lynch L.; Nowak M.; Varghese B.; Clark J.; Hogan A.; Toxavidis V.; Balk S.; O'Shea D.; O'Farrelly C.; Exley M. (2012) 'Adipose Tissue Invariant NKT Cells Protect against Diet-Induced Obesity and Metabolic Disorder through Regulatory Cytokine Production'. Immunity, 37 (3):574-587. [DOI] [Full-Text]
2012 Farah N.; Hogan A.; O'Connor N.; Kennelly M.; O'Shea D.; Turner M. (2012) 'Correlation between maternal inflammatory markers and fetomaternal adiposity'. Cytokine, 60 (1):96-99. [DOI] [Full-Text]
2011 O'Reilly V.; Zeng S.; Bricard G.; Atzberger A.; Hogan A.; Jackson J.; Feighery C.; Porcelli S.; Doherty D. (2011) 'Distinct and overlapping effector functions of expanded human CD4 +, cd8α + and CD4 -CD8α - invariant natural killer T cells'. PLoS ONE, 6 (12). [DOI] [Full-Text]
2011 Hogan, AE; O'Reilly, V; Dunne, MR; Dere, RT; Zeng, SJG; O'Brien, C; Amu, S; Fallon, PG; Exley, MA; O'Farrelly, C; Zhu, XM; Doherty, DG (2011) 'Activation of human invariant natural killer T cells with a thioglycoside analogue of alpha-galactosylceramide'. Journal of Clinical Immunology, 140 :196-207. [DOI] [Full-Text]
2011 Hogan, AE; Tobin, AM; Ahern, T; Corrigan, MA; Gaoatswe, G; Jackson, R; O'Reilly, V; Lynch, L; Doherty, DG; Moynagh, PN; Kirby, B; O'Connell, J; O'Shea, D (2011) 'Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: lessons from obesity, diabetes and psoriasis'. Diabetologia, 54 :2745-2754. [DOI] [Full-Text]
2011 Michielsen, AJ; Hogan, AE; Marry, J; Tosetto, M; Cox, F; Hyland, JM; Sheahan, KD; O'Donoghue, DP; Mulcahy, HE; Ryan, EJ; O'Sullivan, JN (2011) 'Tumour Tissue Microenvironment Can Inhibit Dendritic Cell Maturation in Colorectal Cancer'. PLoS ONE, 6 . [DOI] [Full-Text]
2011 Hogan, AE; Corrigan, MA; O'Reilly, V; Gaoatswe, G; O'Connell, J; Doherty, DG; Lynch, L; O'Shea, D (2011) 'Cigarette smoke alters the invariant natural killer T cell function and may inhibit anti-tumor responses'. Journal of Clinical Immunology, 140 :229-235. [DOI] [Full-Text]


Year Publication
2020 Pisarska M.M.; Dunne M.R.; O'Shea D.; Hogan A.E. (2020) Interleukin-17 producing mucosal associated invariant T cells - emerging players in chronic inflammatory diseases?. [Reviews] [DOI] [Full-Text]
Certain data included herein are derived from the © Web of Science (2024) of Clarivate. All rights reserved.